3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Leukemia, Myeloid, Acute
55
Precursor Cell Lymphoblastic Leukemia-Lymphoma
45
Myelodysplastic Syndromes
42
Leukemia, Lymphocytic, Chronic, B-Cell
40
Leukemia
38
Lymphoma, Non-Hodgkin
32
Multiple Myeloma
31
Lymphoma
31
Lymphoma, Mantle-Cell
26
Lymphoma, Follicular
24
Lymphoma, Large B-Cell, Diffuse
23
Hodgkin Disease
22
Melanoma
21
Burkitt Lymphoma
19
Lymphoma, B-Cell, Marginal Zone
18
Leukemia, Myelomonocytic, Chronic
17
Recurrence
14
Anemia, Refractory, with Excess of Blasts
14
Congenital Abnormalities
13
Neoplasms, Plasma Cell
12
Myeloproliferative Disorders
12
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
11
Lymphoma, Large-Cell, Immunoblastic
11
Hematologic Neoplasms
11
Leukemia, Myeloid, Chronic-Phase
10
Primary Myelofibrosis
9
Lymphoma, Large-Cell, Anaplastic
9
Lymphoma, B-Cell
9
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
9
Ovarian Neoplasms
8
Interventions
Sorafenib
20
Bevacizumab
7
pembrolizumab
5
Oxaliplatin
5
Melphalan
5
Leucovorin
5
Irinotecan
5
Nivolumab
4
Ipilimumab
4
Fluorouracil
4
Cyclophosphamide
4
Capecitabine
4
fludarabine
3
Sirolimus
3
Radiosurgery
3
Gemcitabine
3
Filgrastim
3
Carboplatin
3
toripalimab
2
spartalizumab
2
regorafenib
2
pazopanib
2
lenvatinib
2
ixabepilone
2
durvalumab
2
atezolizumab
2
Vorinostat
2
Thiotepa
2
Temozolomide
2
Sirtuins
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Liver Neoplasms
×
fludarabine phosphate
×
Clear all
NCT02932956
2025-09-19
GAP
Baylor College of Medicine
Phase 1
Active not recruiting
10 enrolled